Communicable Diseases – UPSC Notes

Communicable Diseases | UPSC Notes | Legacy IAS Bangalore
GS-III · Science & Technology · Health · Epidemiology

Communicable Diseases — Complete UPSC Notes 🦠

Comprehensive notes on infectious diseases caused by bacteria, viruses, protozoa, and fungi. Covers causes, transmission modes, symptoms, treatment, vaccines, and India's disease control programmes. Interactive disease cards for all major pathogens. Current affairs: Mpox PHEIC (August 2024), HMPV surge (2025), Nipah Kerala (2024–2025), India exits WHO malaria High Burden group (2024), End TB 2025 target, and more.

🔵 Bacteria: TB (M. tuberculosis), Leprosy, Whooping cough, Salmonella 🟣 Viruses: HIV, Polio, Dengue, Nipah, Influenza, Mpox, COVID-19, Ebola, Hepatitis 🟢 Protozoa: Malaria (Plasmodium), Kala-azar, Amoebiasis, Sleeping sickness 🟠 Fungi: Aspergillosis, Candidiasis, Ringworm, Athlete's foot 🇮🇳 India exits WHO malaria HBHI group 2024 | Mpox PHEIC Aug 2024 | HMPV surge 2025
📚 Legacy IAS — Civil Services Coaching, Bangalore  ·  Updated: April 2026  ·  All Facts Verified
Section 01 — Foundation

🏥 What Are Communicable Diseases?

💡 The "Invisible Invaders" Analogy

Think of your body as a fortress. Communicable diseases occur when tiny invisible invaders — bacteria (soldiers), viruses (stealth missiles), protozoa (parasites), or fungi (slow-acting agents) — breach the fortress walls. They get in through specific entry points: the air you breathe (TB, influenza), water/food you consume (cholera, typhoid), the bite of a carrier insect (malaria, dengue), or direct contact with another infected person (HIV, Ebola). Once inside, they multiply and damage the fortress — causing symptoms. The key difference from non-communicable diseases: these invaders can spread from person to person, or from animals to humans (zoonotic diseases), and can trigger outbreaks, epidemics, and pandemics.

📌 Key Definitions:
Communicable / Infectious / Transmissible disease: A disease caused by a pathogen (bacterium, virus, fungus, protozoan, parasite) that can spread from an infected person/animal to a susceptible host.
Epidemic: Rapid spread of a disease to a large number of people in a given area over a short period.
Pandemic: An epidemic that spreads across countries or continents (e.g., COVID-19, H1N1 2009).
Zoonosis / Zoonotic disease: A disease that jumps from animals to humans (e.g., Nipah from bats, Rabies from dogs, Bird Flu from poultry, Ebola from bats).
Endemic: A disease constantly present in a particular region (e.g., malaria is endemic in parts of Odisha, Chhattisgarh; Kala-azar in Bihar).
PHEIC: Public Health Emergency of International Concern — declared by WHO (e.g., Mpox PHEIC August 2024).
R₀ (Basic Reproduction Number): Average number of people one infected person infects. R₀ >1 = epidemic grows; R₀ <1 = disease fades. Measles R₀ ≈ 15 (most contagious); COVID-19 Omicron ≈ 8–15; TB ≈ 2–3.

🔄 Modes of Disease Transmission

💨
Airborne / Droplet
Breathing infected droplets/aerosols. TB, Influenza, COVID-19, Measles, Whooping cough, HMPV
🦟
Vector-borne
Bite from infected insect. Malaria (Anopheles), Dengue / Zika / Chikungunya (Aedes), Kala-azar (Sandfly), JE / Nipah (Culex)
💧
Water/Foodborne
Contaminated water or food. Cholera, Typhoid, Hepatitis A&E, Polio, Salmonellosis, Amoebiasis
🤝
Direct / Indirect Contact
Bodily fluids, skin, needles, sexual contact, fomites. HIV, Hepatitis B/C, Ebola, Mpox, Ringworm
Pathogen TypeKey FeaturesMajor DiseasesTreatment
🔵 BacteriaSingle-celled, no nucleus (prokaryote), can survive outside host, have cell wallTB, Leprosy, Cholera, Plague, Typhoid, Tetanus, Whooping cough, Gonorrhoea, Leptospirosis✅ Antibiotics (most effective) | Vaccines for many
🟣 VirusesNot cells — just protein coat + genetic material; must use host cell to replicate; smaller than bacteria; no cell wallHIV/AIDS, Influenza, COVID-19, Dengue, Hepatitis B/C, Polio, Ebola, Nipah, Rabies, Mpox❌ Antibiotics DON'T work; Antivirals (limited); Vaccines crucial
🟢 ProtozoaUnicellular eukaryotes (have nucleus); complex life cycles; often use vectors or contaminated waterMalaria, Kala-azar, Amoebiasis, Giardiasis, Chagas, Sleeping sickness✅ Antiprotozoal drugs (chloroquine, artemisinin for malaria); No vaccines for most
🟠 FungiEukaryotic; include moulds and yeasts; cell wall made of chitin; usually opportunistic (attack weak immune system)Aspergillosis, Candidiasis, Ringworm, Athlete's foot, Cryptococcosis, Mucormycosis (black fungus)✅ Antifungal drugs (fluconazole, amphotericin B); Some topical treatments
Section 02 — Disease Details

🔬 Major Communicable Diseases — Tap to Explore

🔵 Bacterial Diseases — Key Principle: Bacteria are living organisms (unlike viruses). Most can be killed by antibiotics. However, rising Antimicrobial Resistance (AMR) is making many bacteria antibiotic-resistant — a global health emergency. TB is the prime example of AMR risk in India (MDR-TB, XDR-TB).
🫁 Tuberculosis (TB) INDIA #1 burden
Pathogen:Mycobacterium tuberculosis
Transmission:Airborne — droplets from cough/sneeze/spit of infected person. NOT spread by handshake, sharing food, or touching surfaces.
Symptoms:Persistent cough >3 weeks, blood-tinged sputum, chest pain, fever (especially evening), night sweats, fatigue, weight loss ("consumption")
Treatment:BCG vaccine (prevention — given at birth). First-line antibiotics: Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE — 6-month regimen). MDR-TB (Multi-Drug Resistant TB): resistant to Isoniazid + Rifampicin.
India:India has world's highest TB burden (~27% of global TB cases). End TB by 2025 — India's target (5 years before WHO's 2030 goal). Nikshay Portal (2012) — for Drug-Resistant TB. TB Harega Desh Jeetega Campaign (2022). NTEP (National TB Elimination Programme).
⚠️ Trap:TB is NOT spread by handshake, sharing food or drink, or toilet seats — ONLY through air.
🖐️ Leprosy (Hansen's Disease) Eliminated but present
Pathogen:Mycobacterium leprae
Transmission:Droplets from mouth/nose of untreated patient through prolonged close contact. Least infectious of all communicable diseases. NOT spread by casual contact, handshake, sharing food, or toilet seats.
Symptoms:Red patches on skin with loss of sensation (numbness), thickened peripheral nerves, muscle weakness, eye problems. Long incubation period: 2–10 years.
Treatment:Fully curable with Multidrug Therapy (MDT): Rifampicin + Dapsone + Clofazimine. BCG vaccine gives partial protection. Free treatment under National Leprosy Eradication Programme (NLEP).
India:India declared leprosy "eliminated" as a public health problem (prevalence <1/10,000) in 2005. However, India still reports the highest number of new leprosy cases globally (~60% of global cases).
😮 Whooping Cough (Pertussis) Vaccine-preventable
Pathogen:Bordetella pertussis
Transmission:Highly contagious — airborne (sneezes/coughs). Very high R₀ (~15, similar to measles). Most dangerous in infants under 1 year.
Symptoms:Initial mild cold → severe coughing fits with "whoop" (high-pitched gasp for air) → vomiting after cough. Apnoea (breathing stops) and cyanosis (turning blue) in infants — can be fatal.
Treatment:DTaP vaccine (Diphtheria, Tetanus, Pertussis) — part of Universal Immunisation Programme (UIP). Antibiotics (azithromycin, erythromycin) reduce severity if given early. Pentavalent vaccine in India includes pertussis component.
🦠 Salmonellosis / Typhoid Food/water-borne
Pathogen:Salmonella typhi (Typhoid); Salmonella spp. (Salmonellosis)
Transmission:Faecal-oral route — contaminated food and water, poor sanitation. "Disease of dirty hands."
Symptoms:High sustained fever (stepladder pattern in typhoid), headache, abdominal pain, diarrhoea or constipation, nausea, vomiting, rose spots on trunk (typhoid). "Enteric fever" = typhoid fever.
Treatment:Electrolyte replacement, antibiotics (fluoroquinolones — ciprofloxacin, azithromycin). Typhoid vaccine (Ty21a oral, Vi polysaccharide injectable). Typhoid Conjugate Vaccine (TCV) — WHO-recommended, longer protection.
🟣 Viral Diseases — Key Principle: Viruses are NOT alive in the traditional sense — they are genetic material (DNA or RNA) in a protein coat. They CANNOT be killed by antibiotics (antibiotics target bacterial cell walls/metabolism — viruses have neither). Only antivirals (limited spectrum) and vaccines work. Prevention through vaccination is critical for most viral diseases.
🧬 HIV / AIDS No cure — ART manages
Pathogen:Human Immunodeficiency Virus (HIV) — Retrovirus (uses reverse transcriptase: RNA→DNA). Destroys CD4+ T cells (helper T cells) → AIDS when CD4 count <200 cells/μL.
Transmission:Sexual contact (most common), blood/blood products (transfusions, needles), mother to child (vertical — during pregnancy, birth, breastfeeding). CANNOT spread through saliva, sweat, tears, handshake, hugging, mosquito bites.
Diagnosis:ELISA test (screening), Western Blot (confirmation). CD4 cell count and viral load monitoring.
Treatment:No cure. ART (Antiretroviral Therapy) — combination of antiretroviral drugs controls viral load, prevents AIDS progression. Free ART under NACO (National AIDS Control Organisation). India: 84% reduction in mother-to-child HIV transmission (2010–2024) — outpacing global reduction of 56.5%.
⚠️ Trap:HIV ≠ AIDS. HIV is the virus; AIDS is the advanced stage. HIV-positive person may not have AIDS for years with ART.
💉 Poliomyelitis (Polio) India polio-free 2014
Pathogen:Poliovirus (Enterovirus — RNA virus, 3 serotypes: Type 1, 2, 3)
Transmission:Primarily faecal-oral route — contaminated water/food. Droplet spread possible. Mainly affects children under 5 years.
Symptoms:90% infections asymptomatic. Symptomatic: fever, headache, vomiting. <1%: attacks anterior horn cells of spinal cord → irreversible flaccid paralysis. Bulbar polio: attacks brainstem → respiratory failure.
Treatment:No cure. Prevention: (1) OPV (Oral Polio Vaccine — Sabin) — used in mass immunisation campaigns. (2) IPV (Inactivated Polio Vaccine — Salk) — injected, safer for immunocompromised. Pulse Polio Programme — "Do Boond Zindagi Ki."
India:India declared polio-free on 27 March 2014 by WHO — a landmark achievement. Last case in West Bengal in 2011.
🦟 Dengue Fever Aedes mosquito
Pathogen:Dengue virus (Flavivirus — 4 serotypes: DENV-1, 2, 3, 4). Second infection with different serotype → Dengue Haemorrhagic Fever (DHF) / Dengue Shock Syndrome (DSS) — more severe.
Vector:Aedes aegypti mosquito (also transmits Zika, Chikungunya, Yellow fever). Breeds in clean, stagnant water. Bites during daytime (unlike malaria mosquito which bites at night).
Symptoms:High fever, severe headache, "breakbone fever" (severe muscle/joint pain), pain behind eyes, nausea, rash, swollen glands. Bleeding signs in DHF: gums, nose, under skin (petechiae).
Treatment:No specific treatment — supportive care (fluids, paracetamol — NOT aspirin/ibuprofen as they increase bleeding risk). India: CFR below 0.13% (2024) — sustained below 1% since 2008. Cannot spread person-to-person directly. Dengvaxia (vaccine) — approved in some countries, limited use. Spain reported first sexual transmission of dengue (2024) — rare.
🦟 Malaria Plasmodium parasite
Pathogen:Plasmodium parasite — NOT a virus or bacterium (it's a protozoan). 5 species: P. falciparum (most deadly), P. vivax (most common in India), P. malariae, P. ovale, P. knowlesi.
Vector:Female Anopheles mosquito — bites at dusk/night. Male mosquitoes don't bite. Infects and destroys Red Blood Cells (RBCs).
Symptoms:Periodic fever with chills ("cold-hot-sweating" cycle), headache, fatigue, muscle aches. Severe P. falciparum: cerebral malaria (coma), pulmonary oedema, renal failure — can be fatal.
Treatment:Chloroquine (P. vivax), Artemisinin-based Combination Therapy (ACT) for P. falciparum. Primaquine for P. vivax radical cure (kills liver dormant forms). R21/Matrix-M vaccine (WHO approved 2023) — first malaria vaccine. India: 78% drop in cases (2015–2024). Exited WHO HBHI group 2024. Target: elimination by 2030.
🦇 Nipah Virus Kerala recurrent
Pathogen:Nipah virus (NiV) — RNA virus of Paramyxoviridae family. Fruit bats (Pteropus — flying foxes) = natural reservoir.
Transmission:Animals (bats, pigs) → humans. Also human-to-human through direct contact with bodily fluids. Contaminated food (date palm sap contaminated by bat urine/saliva). CFR 40–75%.
Symptoms:Fever, headache, myalgia (muscle pain), vomiting → acute respiratory infection, encephalitis (brain inflammation), seizures, coma. High case fatality rate.
Treatment:No specific treatment or approved vaccine. Supportive care. Monoclonal antibody m102.4 (investigational). India: Kerala has reported repeated outbreaks: 2018 (23 cases, CFR 91%), 2019 (1 case), 2021 (1 case), 2023 (6 cases), 2024 (2 cases, CFR 100%), 2025 (4 cases). Kerala's containment mechanisms are globally recognised.
😷 Influenza 4 types: A, B, C, D
Pathogen:Influenza viruses (Orthomyxoviridae). Types A, B, C, D. Only Type A causes pandemics (H1N1 — Spanish Flu 1918, Swine Flu 2009; H5N1 — Bird Flu). Type D primarily infects cattle.
Transmission:Droplets from cough/sneeze, respiratory secretions, contaminated surfaces. High R₀. Antigenic shift (major change — creates pandemic strains) vs Antigenic drift (minor changes — creates seasonal variants).
Symptoms:Sudden onset fever, chills, severe body aches, headache, dry cough, sore throat, fatigue. More severe than common cold.
Treatment:Annual influenza vaccine (reformulated each year based on WHO-predicted strains). Antivirals: Oseltamivir (Tamiflu), Zanamivir. H5N1 Bird Flu: WHO monitoring closely — limited human-to-human transmission so far. H5N1 cases in India's poultry periodically reported.
🩹 Mpox (Monkeypox) PHEIC Aug 2024
Pathogen:Monkeypox virus (MPXV) — Orthopoxvirus genus. Two clades: Clade I (Central Africa — more severe, includes Clade Ib) and Clade II (West Africa — less severe). First identified in monkeys (1958), first human case 1970 (DRC).
Transmission:Animal-to-human (rodents, primates). Human-to-human: direct physical contact with skin lesions, body fluids, respiratory droplets (prolonged contact needed). NOT highly airborne like COVID. Sexual contact is a common route in recent outbreaks.
Symptoms:Distinctive skin rash (papules → vesicles → pustules → scabs), fever, headache, muscle aches, fatigue, swollen lymph nodes (key distinguishing feature vs smallpox). Self-limiting in 2–4 weeks.
Treatment:Supportive care. Smallpox vaccines (JYNNEOS, ACAM2000) provide cross-protection. Tecovirimat (antiviral) under investigation. WHO declared PHEIC on 14 August 2024 — second Mpox PHEIC (first: July 2022–May 2023). Driven by Clade Ib in DRC. India: 30 confirmed cases (Kerala + Delhi) as of 2024.
🫁 Hepatitis (A, B, C, D, E) 5 types, different routes
Pathogen:5 hepatitis viruses: A, B, C, D, E. All cause liver inflammation (hepatitis = "hepar" liver).
Transmission:Hep A & E: Faecal-oral route — contaminated food/water (waterborne). Acute only. Hep B, C, D: Blood, sexual contact, needle sharing, mother-to-child. Can cause chronic disease. Hep D: ONLY infects people already infected with Hep B (requires HBsAg).
Symptoms:Fatigue, jaundice (yellow skin/eyes — key sign), dark urine, pale stools, nausea, abdominal pain, fever. Chronic Hep B/C → cirrhosis, liver cancer.
Vaccines:Hep A vaccine ✅ | Hep B vaccine ✅ (recombinant — rDNA technology; given at birth under UIP) | Hep E vaccine ✅ (approved in China) | No vaccine for Hep C (treatable with antivirals — Sofosbuvir). Hep B vaccine = rDNA product (uses yeast cells). Nobel Prize Physiology/Medicine 2020: Harvey Alter, Charles Rice, Michael Houghton — discovery of Hepatitis C virus.
🤰 Zika Virus Microcephaly in fetus
Pathogen:Zika virus (Flavivirus — same family as Dengue and JE). First identified in Zika Forest, Uganda (1947).
Vector:Aedes aegypti (same as Dengue). Also: sexual transmission, blood transfusion, mother to fetus during pregnancy.
Symptoms:Mild: fever, rash, headache, joint pain, conjunctivitis. 80% infections are asymptomatic. Danger: Congenital Zika — if pregnant woman infected, fetus can develop microcephaly (abnormally small head/brain), Guillain-Barré syndrome (GBS).
Treatment:No specific treatment or approved vaccine. Supportive care. India 2024: Pune (Maharashtra) reported 103 cases (including pregnant women) since June 2024 — heavy rains increased Aedes breeding.
🫁 HMPV (Human Metapneumovirus) 2025 surge
Pathogen:Human Metapneumovirus (hMPV) — RNA virus of Pneumoviridae family. Discovered 2001. In circulation for 70+ years but newly recognised.
Transmission:Respiratory droplets and contact — similar to influenza and RSV. Spread through cough, sneeze, contaminated surfaces.
Symptoms:Cough, fever, runny nose, shortness of breath — like flu. Can cause bronchiolitis, pneumonia in vulnerable groups. High-risk: children, elderly, immunocompromised.
2025 context:Significant global surge in late 2024 — first reported in China, then spread to USA, India, Pakistan. 17% increase in paediatric hospital admissions (Q1 2025 vs Q1 2023) in USA and China. WHO and ICMR assessed it as expected seasonal trend — no PHEIC declared. No approved vaccine or specific antiviral for hMPV.
🟢 Protozoan Diseases — Key Points: Protozoa are unicellular eukaryotes — more complex than bacteria. Most have intricate life cycles involving a vector (mosquito, sandfly, tsetse fly). Antibiotics don't kill protozoa — specific antiprotozoal drugs needed. Most protozoan diseases are tropical/subtropical. India bears a very large share of the global protozoan disease burden.
🦟 Malaria Anopheles mosquito
Pathogen:Plasmodium spp. (P. falciparum — most lethal; P. vivax — most common in India; P. ovale, P. malariae, P. knowlesi)
Life cycle:Two hosts: Anopheles mosquito (sexual reproduction = definitive host) and Humans (asexual reproduction = intermediate host). Sporozoites → liver → merozoites → RBCs → gametocytes → mosquito.
India 2024:78.1% drop in malaria cases (2015–2024). 77.6% decline in deaths. Annual Parasite Incidence (API) reduced from 0.92 → 0.18. Malaria deaths: 8 lakh/year in 1947 → 76 in 2024. India officially exited WHO High Burden to High Impact (HBHI) group in 2024. Target: eliminate malaria (zero indigenous cases) by 2030. Interim target: interrupt indigenous transmission by 2027.
Programmes:NVBDCP (National Vector Borne Disease Control Programme). Indoor Residual Spraying (IRS). Long-Lasting Insecticidal Nets (LLIN). Artemisinin-based Combination Therapy (ACT). R21/Matrix-M vaccine (WHO approved Oct 2023) — first effective malaria vaccine.
🪲 Kala-azar (Leishmaniasis) Near-eliminated India
Pathogen:Leishmania donovani (visceral leishmaniasis = kala-azar). Other species cause cutaneous (skin) and mucocutaneous forms.
Vector:Bite of infected female phlebotomine sandfly (Phlebotomus argentipes in India).
Symptoms:Prolonged fever, anaemia, massive enlargement of spleen and liver (hepatosplenomegaly), weight loss, weakness. "Kala-azar" = "black fever" in Hindi (skin darkening). Fatal if untreated.
Treatment:Treatable — Liposomal Amphotericin B (most effective, single-dose), Miltefosine (oral). No vaccine. India milestone: Kala-azar elimination target (<1 case per 10,000 population) achieved in 633 blocks across 54 districts — ahead of 2030 SDG target. Endemic states: Bihar, Jharkhand, West Bengal, UP.
💩 Amoebiasis Poor sanitation
Pathogen:Entamoeba histolytica (amoeba). Forms two stages: trophozoite (active, causes disease) and cyst (dormant, infectious, survives outside).
Transmission:Faecal-oral route — contaminated water, food, flies. Common in areas with poor sanitation and inadequate safe water.
Symptoms:Amoebic dysentery: bloody diarrhoea, abdominal cramps, fever. Can cause amoebic liver abscess (severe complication). Many infections are asymptomatic.
Treatment:Metronidazole (kills trophozoites) + Diloxanide furoate (kills cysts). Prevention: safe water, food hygiene, sanitation (link with Swachh Bharat Mission).
🪰 African Sleeping Sickness Sub-Saharan Africa
Pathogen:Trypanosoma brucei (Human African Trypanosomiasis). T. b. gambiense (chronic, West/Central Africa) and T. b. rhodesiense (acute, East Africa).
Vector:Bite of infected tsetse fly (Glossina) — found only in sub-Saharan Africa. Not present in India.
Symptoms:Stage 1 (blood/lymph): fever, headache, joint pain, lymph node swelling. Stage 2 (CNS involvement): confusion, sensory disturbances, loss of coordination, disrupted sleep patterns (sleeping sickness), coma. Fatal if untreated.
Treatment:Antitrypanosomal drugs: Pentamidine (Stage 1), Melarsoprol (Stage 2 — toxic), Eflornithine. Fexinidazole (newer oral drug, 2019 WHO-approved). Chagas disease (American trypanosomiasis): Trypanosoma cruzi, vector = triatomine (kissing) bug.
🟠 Fungal Diseases — Key Points: Fungi are eukaryotes with chitin cell walls. Most fungal infections are opportunistic — they attack people with weakened immune systems (HIV/AIDS patients, diabetics, those on steroids/immunosuppressants). Rising fungal infections are linked to increasing antibiotic use (kills bacteria → allows fungi to flourish) and climate change. Mucormycosis ("Black Fungus") emerged during COVID-19 pandemic in India — seen in immunocompromised COVID patients. Antifungals (fluconazole, voriconazole, amphotericin B) are the treatment.
🫁 Aspergillosis Lung fungal infection
Pathogen:Aspergillus fumigatus (most common), A. flavus, A. niger. Present everywhere in environment — inhaled daily. Causes disease only in immunocompromised.
Types:Allergic Bronchopulmonary Aspergillosis (ABPA) — in asthma/cystic fibrosis. Aspergilloma — "fungus ball" in lung cavity (often after TB). Invasive Aspergillosis — life-threatening in immunocompromised.
Treatment:Voriconazole (first-line), Isavuconazole, Amphotericin B. Surgical removal of aspergilloma in some cases.
🦷 Candidiasis (Thrush) Common opportunistic
Pathogen:Candida albicans (most common), C. auris (drug-resistant, emerging threat). C. auris declared "urgent threat" by CDC — resistant to most antifungals.
Types:Oral thrush (white patches in mouth), genital candidiasis (vaginal yeast infection), invasive candidiasis (bloodstream — serious), oropharyngeal (AIDS patients).
Treatment:Fluconazole (most candida), Echinocandins (for C. auris). Topical antifungals (clotrimazole) for skin/mucosal infections.
👟 Athlete's Foot (Tinea Pedis) Dermatophyte fungi
Pathogen:Trichophyton, Epidermophyton, Microsporum — collectively "dermatophytes." Feed on keratin (skin, hair, nails).
Transmission:Direct contact with infected skin or contaminated surfaces (floors, towels, shoes). Thrives in warm, moist environments.
Symptoms:Itchy, scaly, cracked skin between toes. Blistering. Can spread to nails (onychomycosis) and groin (tinea cruris = jock itch).
Treatment:Topical antifungals (clotrimazole, miconazole, terbinafine). Keep feet dry; wear breathable footwear; avoid walking barefoot in public.
Ringworm (Tinea Corporis) No actual worm!
Pathogen:Dermatophyte fungi (Trichophyton, Microsporum). Despite the name — NO worm is involved! The ring-shaped rash looks like a worm under the skin.
Types:Tinea capitis (scalp — causing hair loss), Tinea corporis (body), Tinea cruris (groin), Tinea unguium (nails = onychomycosis).
Transmission:Direct contact with infected person, animal (cats/dogs), or contaminated objects. Sharing towels, combs, clothing.
Treatment:Topical antifungals (clotrimazole, terbinafine). Oral antifungals (griseofulvin, itraconazole) for scalp/nail infections.
⚠️ UPSC trap:Ringworm is caused by FUNGI — not a worm. Tinea = dermatophyte fungal infection.
Section 03 — Quick Reference

🦟 Disease-Vector-Pathogen Master Table

DiseasePathogen TypeCausative AgentVector / RouteNo Vaccine?
MalariaProtozoaPlasmodium spp.Female Anopheles mosquitoR21 vaccine approved 2023 ✅
DengueVirus (Flavivirus)DENV 1–4Female Aedes aegypti mosquitoLimited (Dengvaxia); no universal vaccine ❌
ZikaVirus (Flavivirus)Zika virusFemale Aedes aegypti mosquitoNo vaccine ❌
ChikungunyaVirus (Alphavirus)CHIKVFemale Aedes aegypti / A. albopictusIXCHIQ vaccine approved 2023 (USA) ✅
Japanese Encephalitis (JE)Virus (Flavivirus)JE virusCulex mosquito (pigs/birds are amplifying hosts)JE vaccine ✅ (SA 14-14-2 live attenuated)
Kala-azar (Leishmaniasis)ProtozoaLeishmania donovaniFemale phlebotomine sandflyNo vaccine ❌
Lymphatic FilariasisNematode (worm)Wuchereria bancroftiCulex mosquitoNo vaccine; MDA (DEC+Albendazole) ❌
PlagueBacteriaYersinia pestisFleas on rats (bubonic); droplets (pneumonic)Vaccine available (limited use) ✅
African Sleeping SicknessProtozoaTrypanosoma bruceiTsetse fly (Africa only)No vaccine ❌
Chagas diseaseProtozoaTrypanosoma cruziTriatomine (kissing) bug (Americas)No vaccine ❌
Typhus (Scrub)Bacteria (Rickettsia)Orientia tsutsugamushiChigger mite biteNo vaccine ❌
Lyme diseaseBacteriaBorrelia burgdorferiIxodes tick biteVaccine under development

💉 India's Universal Immunisation Programme (UIP) — Disease-Vaccine Map

VaccineDisease Protected AgainstGiven AtType
BCGTuberculosis (partial), Leprosy (partial)BirthLive attenuated bacteria
OPV (Oral Polio)PoliomyelitisBirth + 6, 10, 14 weeks + boostersLive attenuated virus (Sabin)
IPV (Inactivated Polio)Poliomyelitis6 weeks + boostersKilled virus (Salk)
PentavalentDiphtheria, Pertussis, Tetanus, Hep B, Hib6, 10, 14 weeksCombined killed/toxoid
RotavirusRotavirus diarrhoea6, 10, 14 weeksLive attenuated
MMRMeasles, Mumps, Rubella9 months, 15 monthsLive attenuated virus
JE (SA 14-14-2)Japanese Encephalitis9 months + 16–24 months (endemic areas)Live attenuated
Hepatitis BHepatitis BBirth + 6, 10, 14 weeks (in Pentavalent)Recombinant (rDNA)
Typhoid (TCV)Typhoid fever9 months–15 years (high-burden areas)Conjugate vaccine
Vitamin AVitamin A deficiency; reduces measles severity9 months, then biannually to 5 yearsMicronutrient supplement (not a vaccine)
Section 04 — Current Affairs

📰 Current Affairs 2024–2026 (Fact-Verified)

Aug 2024 — 🌍 WHO Mpox declared PHEIC — 14 August 2024 (Second PHEIC for Mpox)
📜 What:WHO declared Mpox a Public Health Emergency of International Concern (PHEIC) on 14 August 2024 — the second Mpox PHEIC in two years (first: July 2022–May 2023). This time driven by a more severe variant: Clade Ib, spreading rapidly in Democratic Republic of Congo (DRC) and neighbouring African countries.
🔬 Clade Ib:A more transmissible sub-variant of Clade I (Central African clade). Spreads more easily via sexual contact and close physical contact. More severe than Clade IIb (which caused the 2022 global outbreak). Primarily affecting DRC, Burundi, Rwanda, Uganda. As of Sept 2024, India reported its first case of Clade 1b strain.
🇮🇳 India:Total of 30 laboratory-confirmed cases as of 2024 — from Kerala (15) and Delhi (15). Most with international travel history. One death in Kerala. First cases reported July 2022.
💊 Treatment:No approved vaccine specifically for Clade Ib. Smallpox vaccines (JYNNEOS, ACAM2000) cross-protective. Tecovirimat (antiviral) under investigation in PALM007 and STOMP clinical trials. Mpox self-limiting in ~2–4 weeks in healthy individuals.
📚 UPSC angle:Mpox; PHEIC; Clade I vs Clade II; Orthopoxvirus; WHO emergency declarations; zoonotic disease; cross-protection from smallpox vaccines.
Early 2025 — 🌍 GLOBAL HMPV Surge 2025 — Human Metapneumovirus: Not a Pandemic, but Notable
📈 Surge:Significant global surge in Human Metapneumovirus (hMPV) cases in late 2024–early 2025. First reported prominently in China, then USA, India, Pakistan. 17% increase in paediatric hospital admissions (Q1 2025 vs Q1 2023) in USA and China.
🔬 Virus:hMPV — RNA virus discovered in 2001 (Netherlands). Has been circulating globally for 70+ years. Causes respiratory infections similar to RSV and Influenza. Two lineages (A and B). No approved vaccine or specific antiviral.
🇮🇳 India:Cases reported across multiple states in early 2025 — Karnataka, Tamil Nadu, Gujarat, others. ICMR and MoHFW assessed the situation as a seasonal respiratory surge — no PHEIC warranted. WHO guidance: standard respiratory precautions sufficient.
📚 UPSC angle:hMPV; emerging respiratory viruses; IHIP (Integrated Health Information Platform) surveillance; ICMR; importance of distinguishing between epidemic alert vs public health emergency.
2024–2025 — 🇮🇳 INDIA India's Malaria Milestone: Exits WHO High Burden Group + 78% Case Reduction
🏆 Achievement:India officially exited the WHO High Burden to High Impact (HBHI) group in 2024 — a major milestone recognising sustained reductions in malaria incidence and mortality in high-endemic states.
📊 Data:78.1% drop in malaria cases (2015–2024). 77.6% decline in deaths. Annual Parasite Incidence (API): 0.92 → 0.18. Malaria deaths: 8 lakh/year (1947) → 384 (2015) → 76 (2024). No malaria cases in 122 districts. 34 States/UTs with API <1 (except Tripura: 5.69, Mizoram: 14.23).
🎯 Targets:Interim: Interrupt indigenous transmission by 2027. Final: Eliminate malaria (zero indigenous cases) by 2030. Malaria vaccine R21/Matrix-M (WHO approved October 2023) — Ghana, Nigeria deploying.
📚 UPSC angle:NVBDCP; HBHI group; API (Annual Parasite Incidence); P. falciparum vs P. vivax; Anopheles; ACT treatment; R21 vaccine; National Framework for Malaria Elimination 2016-2030; global malaria target 75% reduction by 2025.
2024–2025 — 🇮🇳 KERALA Nipah Virus: Recurring Outbreaks in Kerala (2024 & 2025)
📊 Outbreaks:Kerala has become the focal point of Nipah in India: 2018 (23 cases, CFR 91%), 2019 (1 case), 2021 (1 case), 2023 (6 cases, 2 deaths), 2024 (2 cases, CFR 100%), 2025 (4 confirmed cases as of May–July 2025; 2 deaths). Nine outbreaks in Kerala since 2018.
🦇 Source:Fruit bats (Pteropus) = natural reservoir. Transmission to humans via contact with bat urine/saliva (contaminated fruit, date palm sap), infected pigs, or infected humans. No sustained human-to-human chains observed in Kerala outbreaks.
🏥 Response:Kerala's containment model — rapid contact tracing, isolation, surveillance — is globally recognised. ICMR provided m102.4 monoclonal antibody (experimental) to contacts in 2023 outbreak. WHO classifies Nipah as a Priority Pathogen (potential pandemic threat, BSL-4 pathogen).
📚 UPSC angle:Nipah; zoonotic disease; fruit bats; CFR; Kerala's outbreak response; One Health approach; WHO Priority Pathogens list; BSL-4 (Bio-Safety Level) laboratories; ICMR; pandemic preparedness.
2024–2025 — 🇮🇳 INDIA India's Disease Control Milestones: Kala-azar, JE, HIV, Filariasis
🏆 Kala-azar:Elimination target (<1 case per 10,000 population) achieved in 633 blocks across 54 districts of endemic states — ahead of 2030 SDG target. Status maintained.
🧠 JE (Japanese Encephalitis):Case Fatality Rate (CFR) reduced from 17.6% (2014) → 7.1% (2024). Success of JE vaccination programme in endemic districts of UP, Bihar, Assam.
🔴 HIV:84% reduction in mother-to-child HIV transmission (2010–2024) — outpacing global reduction of 56.5%. 74.5% drop in transmission rate. NACO's PPTCT (Prevention of Parent-to-Child Transmission) programme.
🦟 Filariasis:Mass Drug Administration (MDA) coverage for Lymphatic Filariasis rose from 75% (2014) → 85% (2025). Target: eliminate LF by 2027. India accounts for ~40% of global LF burden.
📊 Surveillance:Integrated Health Information Platform (IHIP) — successor to IDSP — monitors 50+ epidemic-prone diseases via paperless, case-based reporting with geotagged heat maps for early detection. Dengue CFR: 0.13% in 2024 (below 1% since 2008).
Section 05 — PYQs & MCQs

📝 Previous Year Questions & Practice MCQs

PYQ — Prelims 2019 Consider the following pairs (Disease — Causative Organism):
1. Kala-azar — Leishmania donovani
2. Malaria — Plasmodium vivax
3. Sleeping sickness — Trypanosoma brucei
4. Filariasis — Wuchereria bancrofti
Which of the above pairs are correctly matched?
a) 1, 2 and 3 only
b) 1 and 4 only
c) 1, 2, 3 and 4
d) 2, 3 and 4 only
All four pairs are correctly matched! Pair 1 ✓ — Kala-azar (Visceral Leishmaniasis) is caused by Leishmania donovani, transmitted by the phlebotomine sandfly. India (Bihar, Jharkhand, WB, UP) accounts for a large share of global cases. Near-eliminated in India (633 blocks achieved <1/10,000 target). Pair 2 ✓ — Malaria in India is predominantly P. vivax (also P. falciparum — more deadly). P. vivax has a dormant liver stage (hypnozoites) that can relapse months-years later — requires Primaquine for radical cure. P. falciparum causes cerebral malaria, the most deadly form. Pair 3 ✓ — African Sleeping Sickness is caused by Trypanosoma brucei, transmitted by the tsetse fly in sub-Saharan Africa. T. brucei gambiense (West/Central Africa — chronic) and T. brucei rhodesiense (East Africa — acute). Not present in India. Pair 4 ✓ — Lymphatic Filariasis (Elephantiasis) is caused by Wuchereria bancrofti (>90% of cases) and Brugia malayi. Transmitted by Culex mosquito. Causes lymphatic blockage → gross swelling of limbs (elephantiasis). India has 40% of global burden. MDA programme: DEC + Albendazole. Answer: (c).
PYQ — Prelims 2021 Which of the following statements is/are correct about tuberculosis?
1. TB is caused by Mycobacterium tuberculosis and spreads through contaminated food and water.
2. BCG vaccine protects against all forms of tuberculosis.
3. India has set a target to end TB by 2025 — five years ahead of the global 2030 target.
4. MDR-TB refers to tuberculosis resistant to at least Isoniazid and Rifampicin.
a) 1 and 3 only
b) 2 and 4 only
c) 3 and 4 only
d) 1, 3 and 4 only
Statement 1 ✗ — Classic UPSC trap: TB does NOT spread through contaminated food or water. TB is spread ONLY through the AIR — when an infected person coughs, sneezes, or spits, they release droplet nuclei containing M. tuberculosis. The droplets can remain suspended in the air for hours. TB is NOT spread by sharing food, water, handshakes, or touching toilet seats. This distinction is very frequently tested. Statement 2 ✗ — BCG (Bacillus Calmette-Guérin) vaccine does NOT protect against all forms of TB. It provides good protection against severe forms of childhood TB (TB meningitis, miliary TB) but gives variable and often inadequate protection against pulmonary TB (the most common adult form) — which is why TB continues to spread despite BCG. Statement 3 ✓ — India has set an ambitious target to End TB by 2025 — five years before the WHO's global End TB Strategy target of 2030. NTEP (National TB Elimination Programme), TB Harega Desh Jeetega campaign, Nikshay Portal (for drug-resistant TB), and Nikshay Poshan Yojana (nutritional support) are key initiatives. Statement 4 ✓ — MDR-TB (Multi-Drug Resistant TB) is defined as TB resistant to at least Isoniazid AND Rifampicin — the two most powerful first-line anti-TB drugs. XDR-TB (Extensively Drug Resistant) = MDR-TB + resistance to any fluoroquinolone + at least one second-line injectable. Answer: (c).
Q1 Consider the following statements:
1. Aedes aegypti mosquito transmits Dengue, Zika, and Chikungunya.
2. Anopheles mosquito transmits malaria — only the female mosquito bites humans.
3. Dengue can spread directly from person to person without a mosquito vector.
4. Culex mosquito transmits Japanese Encephalitis and Lymphatic Filariasis.
a) 1, 2 and 3 only
b) 1, 2 and 4 only
c) 2, 3 and 4 only
d) 1, 2, 3 and 4
Statement 1 ✓ — Aedes aegypti (and Aedes albopictus — tiger mosquito) transmits multiple arboviruses: Dengue (DENV 1-4), Zika virus, Chikungunya virus, and Yellow fever virus. Distinctive features: has white/silver striping, bites during daytime, breeds in clean stagnant water (flower pots, tyres, coolers, containers). Statement 2 ✓ — Only female mosquitoes (of all species) bite humans — they need blood protein for egg production. Male mosquitoes feed only on nectar. In Anopheles: only the female carries and transmits Plasmodium parasites. Bites predominantly between dusk and dawn. Rests with its body at an angle to the surface (distinguishes from Culex which rests parallel). Statement 3 ✗ — Important trap: Dengue CANNOT spread directly from person to person. The virus requires an Aedes mosquito as an intermediate vector — a human cannot infect another human directly. Exception: very rare maternal transmission (mother to baby during pregnancy). Spain reported the first confirmed sexual transmission in 2024 — but this is extremely rare, not a standard route. Statement 4 ✓ — Culex mosquito transmits: Japanese Encephalitis (JE — with pigs and birds as amplifying hosts), Lymphatic Filariasis (Wuchereria bancrofti), and West Nile Virus. Culex bites at night, breeds in stagnant/dirty water (drains, puddles). Answer: (b).
Q2 Which of the following pairs of disease and vaccine is/are correctly matched?
1. Poliomyelitis — OPV (Oral Polio Vaccine) uses live attenuated poliovirus
2. Hepatitis B — recombinant DNA vaccine produced in yeast cells
3. Tuberculosis — BCG vaccine protects against all forms of pulmonary TB
4. Malaria — R21/Matrix-M vaccine received WHO approval in 2023
a) 1, 2 and 3 only
b) 1, 2 and 4 only
c) 2, 3 and 4 only
d) 1 and 3 only
Statement 1 ✓ — OPV (Oral Polio Vaccine = Sabin vaccine) uses live attenuated (weakened) poliovirus — given orally. IPV (Inactivated Polio Vaccine = Salk vaccine) uses killed virus — injected. OPV is preferred for mass immunisation (cheap, easy, creates gut immunity, can spread vaccine virus to contacts — "herd vaccination"). IPV is safer for immunocompromised individuals but more expensive. India uses both: IPV for primary schedule + OPV for Pulse Polio campaigns. Statement 2 ✓ — Hepatitis B vaccine is produced using recombinant DNA technology — the gene for HBsAg (Hepatitis B surface antigen) is inserted into yeast cells, which produce the antigen protein. This is then purified and used as the vaccine. It was one of the first commercial vaccines produced using rDNA technology (1986). Given at birth under UIP in India. Statement 3 ✗ — This is a key factual error. BCG (Bacillus Calmette-Guérin — live attenuated Mycobacterium bovis) provides GOOD protection against severe childhood forms (TB meningitis, miliary TB) but POOR and VARIABLE protection against pulmonary (lung) TB — which is the most common and transmissible form. This is why TB persists globally despite widespread BCG vaccination. Statement 4 ✓ — R21/Matrix-M malaria vaccine received WHO prequalification and recommendation in October 2023. It is the second malaria vaccine to receive WHO approval (after RTS,S/AS01 — Mosquirix in 2021). R21 showed >75% efficacy in African children. No malaria vaccine has been deployed in India's UIP yet. Answer: (b).
Q3 With reference to HIV/AIDS, which of the following statements is/are correct?
1. HIV is a retrovirus that uses reverse transcriptase to convert its RNA genome into DNA inside host cells.
2. HIV can be transmitted through saliva, sweat, mosquito bites, and casual contact like handshaking.
3. ART (Antiretroviral Therapy) can cure HIV if started early enough.
4. India has achieved an 84% reduction in mother-to-child HIV transmission between 2010 and 2024.
a) 1, 2 and 4 only
b) 1, 2 and 3 only
c) 1 and 4 only
d) 2 and 3 only
Statement 1 ✓ — HIV is indeed a Retrovirus (Family: Retroviridae, Genus: Lentivirus). It carries its genetic material as RNA. Inside the host cell (CD4+ T cell, macrophage, dendritic cell), the enzyme reverse transcriptase converts the viral RNA into DNA — which is then integrated into the host's chromosome (as a "provirus") by the enzyme integrase. The host cell then produces new viral particles. This RNA→DNA process is the reverse of the normal cellular DNA→RNA flow — hence "retrovirus." ART drugs target different steps: Reverse Transcriptase Inhibitors (RTIs), Protease Inhibitors (PIs), Integrase Inhibitors. Statement 2 ✗ — Critically important fact: HIV is NOT transmitted through saliva, sweat, tears, casual contact, handshaking, hugging, sharing food/water, or mosquito bites. HIV transmission requires: sexual contact (vaginal/anal/oral), blood/blood products (transfusions, shared needles, needle-stick injuries), or vertical transmission (mother to child during pregnancy, childbirth, or breastfeeding). This misconception causes enormous social stigma against HIV-positive people — UPSC tests awareness of this. Statement 3 ✗ — ART (Antiretroviral Therapy) CANNOT cure HIV. ART suppresses the viral load to undetectable levels, prevents AIDS progression, protects the immune system, and prevents transmission (U=U: Undetectable = Untransmittable). However, HIV remains integrated in "latent reservoirs" (resting CD4 cells) — permanently. If ART is stopped, the virus rebounds. There is currently no cure for HIV. A small number of people have been functionally cured through bone marrow transplants (Timothy Ray Brown - "Berlin patient"), but this is not scalable. Statement 4 ✓ — India achieved an 84% reduction in mother-to-child HIV transmission (2010–2024), compared to the global reduction of 56.5% — India's progress outpaced the global average. Through the PPTCT (Prevention of Parent-to-Child Transmission) programme. Answer: (c).
Section 06

🧠 Memory Aid — Lock These In

🔑 Communicable Diseases — Critical Facts for UPSC

VECTORS
Anopheles ♀ → Malaria (Plasmodium) | Aedes ♀ → Dengue, Zika, Chikungunya, Yellow fever | Culex ♀ → JE, Filariasis, West Nile | Sandfly → Kala-azar (Leishmania) | Tsetse fly → Sleeping sickness (Trypanosoma) | Ticks → Lyme disease, Typhus | Fleas → Plague (Yersinia pestis)
BACTERIA
TB → Mycobacterium tuberculosis → airborne ONLY (not food/water — TRAP). BCG = partial protection. MDR-TB = resistant to Isoniazid+Rifampicin. Leprosy → M. leprae → MDT curable. Whooping cough → Bordetella pertussis → DTaP vaccine. Salmonella → faecal-oral. India End TB target: 2025 (5 yrs before WHO 2030).
VIRUSES
Antibiotics DON'T work on viruses. HIV = retrovirus (RNA→DNA, reverse transcriptase). HIV NOT transmitted by saliva/sweat/mosquito. ART manages but DOESN'T cure. Polio-free India 2014. Hepatitis D ONLY with Hep B. No vaccine for Hep C (but treatable). Nobel 2020 = Hep C discovery. Mpox PHEIC Aug 2024 (Clade Ib). Zika → microcephaly in fetus. Only Influenza Type A causes pandemics. HMPV surge 2025 (no PHEIC).
PROTOZOA
Malaria = Plasmodium (NOT virus/bacteria). P. falciparum = most deadly. P. vivax = most common in India + relapses (hypnozoites). India exits HBHI group 2024. 78% malaria case drop 2015–2024. Elimination target 2030. Kala-azar = Leishmania donovani (sandfly). Elimination target achieved 633 blocks. Amoebiasis = Entamoeba histolytica (faecal-oral). Sleeping sickness = Trypanosoma brucei (tsetse fly — NOT in India).
FUNGI
Opportunistic — attack weak immune system. Ringworm = fungi, NOT a worm (TRAP!). Mucormycosis ("black fungus") surged during COVID-19 in India. Candida auris = drug-resistant, emerging threat. Aspergillus → lung infections in immunocompromised. Antifungals: Fluconazole, Amphotericin B, Voriconazole.
TRAPS 🪤
• TB = airborne (NOT food/water). • Dengue = NOT person-to-person directly. • HIV = NOT by saliva/sweat/mosquito. • Ringworm = FUNGI (no worm). • Malaria = PROTOZOA (not virus/bacteria). • BCG = partial TB protection (not all forms). • Hep D = only with Hep B. • Only Influenza Type A causes pandemics. • ART manages HIV — does NOT cure. • Mpox PHEIC Aug 2024 = SECOND PHEIC (first was 2022). • OPV = live virus; IPV = killed virus. • Dengue 4 serotypes — second infection with different serotype → more severe (DHF).
CURRENT AFFS
Mpox PHEIC: 14 Aug 2024, Clade Ib, 30 India cases. HMPV surge: 2025, not PHEIC, no vaccine. Malaria India: exits HBHI 2024, 78% case drop, 2030 target. Nipah Kerala: 2024 (2 cases, 100% CFR), 2025 (4 cases). Kala-azar: elimination achieved 633 blocks, ahead of SDG. HIV mother-child: 84% reduction India (2010-2024). JE CFR: 17.6% → 7.1% (2014–2024). Dengue CFR: 0.13% (2024). Filariasis MDA: 85% coverage (2025). R21 malaria vaccine: WHO approved Oct 2023.
Section 07

❓ FAQs — Concept Clarity

What is the difference between an epidemic, a pandemic, and an endemic? With examples.
These three terms describe the geographic spread and prevalence of disease: Endemic: A disease that is consistently present in a specific geographic area or population at a relatively stable rate — it's "native" to that region. Examples: Malaria is endemic in parts of Odisha, Chhattisgarh, Jharkhand, and Mizoram (India). Kala-azar is endemic in Bihar, Jharkhand, and West Bengal. Dengue is endemic in tropical and subtropical regions. The disease doesn't disappear — it maintains a steady baseline level. Epidemic: A sudden, rapid increase in the number of cases of a disease beyond what is normally expected in a specific area within a short time. Examples: COVID-19 outbreak in Wuhan (December 2019) was an epidemic before it became a pandemic. Nipah outbreaks in Kerala (2018, 2019, etc.) are epidemics. Cholera outbreaks in flood-affected areas. A disease that is endemic can have epidemic peaks — e.g., dengue cases spike every monsoon in India. Pandemic: An epidemic that has spread over a large geographic area (multiple countries/continents) affecting a large number of people. Examples: COVID-19 (2020–2022) — declared pandemic by WHO on 11 March 2020. Influenza H1N1 "Spanish Flu" (1918) — 50 million deaths. H1N1 Swine Flu (2009) — first pandemic of 21st century. HIV/AIDS — ongoing pandemic. Mpox 2022-23 was a global outbreak but WHO did not classify it as a pandemic.
Why are viral diseases generally harder to treat than bacterial diseases?
This is a fundamental question in microbiology with important policy implications. Bacteria are living organisms: They have their own cell walls, ribosomes, DNA replication machinery, and metabolic processes that are distinctly different from human cells. Antibiotics exploit these differences — penicillin targets bacterial cell wall synthesis (which human cells don't have), fluoroquinolones target bacterial DNA gyrase (different from human topoisomerase). This selective toxicity — killing bacteria while sparing human cells — is what makes antibiotics effective and relatively safe. Viruses are NOT cells: They are tiny packages of genetic material (DNA or RNA) wrapped in a protein coat. They have NO cell wall, NO ribosomes, NO independent metabolism. To replicate, they completely hijack the host cell's own machinery — using the host's ribosomes, enzymes, and energy. This means any drug that blocks viral replication often also disrupts normal cell function → toxicity to the host. Developing antivirals that selectively target viral processes without harming host cells is extremely challenging. For example, HIV reverse transcriptase is unique to retroviruses (human cells don't have it) — so RTI drugs can selectively target it. But for many viruses, there are no such unique targets. Policy implication: Vaccines are the primary tool for viral diseases — they prime the immune system to recognise and destroy the virus before it establishes infection. For UPSC: This explains why COVID-19, dengue, Nipah, Zika have no specific treatment — their replication is too intertwined with host cell machinery. And why antibiotics should NEVER be given for viral infections — they are useless and worsen antibiotic resistance.
What is "One Health" and why is it relevant to communicable diseases like Nipah and H5N1?
The "One Health" concept recognises that human health, animal health, and environmental health are deeply interconnected — and that diseases cannot be managed by focusing on any one in isolation. Approximately 60–75% of emerging infectious diseases are zoonotic (originating in animals). Nipah virus (bats → pigs/humans), H5N1 Bird Flu (poultry → humans), Ebola (bats → apes → humans), COVID-19 (bats → [intermediate host?] → humans), Nipah in Kerala (bats → humans) — all are zoonotic. One Health applications: (1) Joint surveillance by veterinary and human health authorities — detecting animal outbreaks before they spillover to humans. (2) Monitoring wildlife-livestock-human interfaces — Kerala's fruit bat colonies living near human settlements is a classic One Health concern. (3) Antibiotic resistance — overuse of antibiotics in livestock creates resistant bacteria that spread to humans. (4) Food safety — monitoring pathogens in the food chain (Salmonella in poultry, H5N1 in eggs). India's context: ICMR has a National Centre for One Health (NCOH). The National Action Plan on AMR (Antimicrobial Resistance) includes a One Health component. Nipah response in Kerala uses a One Health approach — coordinating health, veterinary, and forest departments. WHO, FAO, and UNEP jointly promote One Health. UPSC relevance: One Health appears in UPSC questions relating to emerging infectious diseases, AMR, zoonosis, and India's public health preparedness.
Section 08

🏁 Conclusion — UPSC Synthesis

🦠 From Pandemics to Prevention — The Policy Challenge

India's fight against communicable diseases is a story of two simultaneous narratives. The first is one of remarkable success: malaria deaths fell from 8 lakh annually in 1947 to just 76 in 2024 — a 99.99% reduction. India eliminated polio in 2014. Kala-azar is at the threshold of elimination. HIV mother-to-child transmission has been cut 84% in 14 years. These achievements rival anything in global public health history. The second narrative is one of persistent challenge and emerging threats: India carries the world's highest TB burden despite decades of treatment programmes. Nipah returns to Kerala every year. Mpox was declared a PHEIC in August 2024. HMPV caused global alarm in early 2025. The lesson is clear — communicable disease control requires sustained surveillance, universal vaccination, strong primary healthcare, and the "One Health" approach that treats human, animal, and environmental health as one.

📋 Prelims Key Facts
🦟 Anopheles → Malaria | Aedes → Dengue, Zika | Culex → JE, Filariasis
🔵 TB = airborne ONLY (not food/water — trap!)
🔴 HIV NOT by saliva/sweat/mosquito
⭕ Ringworm = FUNGI (not a worm!)
🩸 Malaria = PROTOZOA (not virus)
🇮🇳 India polio-free 2014 | End TB target 2025
🦠 Mpox PHEIC: 14 Aug 2024 (Clade Ib)
🏆 India exits WHO HBHI malaria group 2024
💉 BCG = partial TB protection only
🟣 Hep D = only with Hep B | No vaccine for Hep C
🏥 R21 malaria vaccine: WHO Oct 2023
📝 Mains GS-II/III Topics
🔬 One Health: zoonosis, AMR, surveillance
🇮🇳 India's disease elimination programmes
💉 UIP (Universal Immunisation Programme)
🦠 Pandemic preparedness: Nipah, Mpox, HMPV
🦟 Vector-borne disease control: NVBDCP
🏥 NTEP (End TB), MDR-TB, AMR challenge
🩸 HIV/AIDS: NACO, PPTCT, ART access
🏆 Disease surveillance: IDSP → IHIP
⚖️ PHEIC declarations: WHO's role
🌍 SDG 3.3: End epidemics of AIDS, TB, malaria, NTDs

Book a Free Demo Class

April 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
27282930  
Categories

Get free Counselling and ₹25,000 Discount

Fill the form – Our experts will call you within 30 mins.